Volume 42, number 3: Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampbin and Pyrazinamide for Latent Tuberculosis Infection
4th Jan 2006, 23:27 GMT
Background. Severe liver injuries were attributed to the rifampin and pyrazinamide (RZ) regimen after it was recommended for treating latent tuberculosis infection. Implicating RZ as the likeliest cause required excluding alternative causes. Methods. US health departments reported data on patients who died or were hospitalized for liver disease within 1 month after taking RZ for latent tuberculosis infection from October 1998 through March 2004. The circumstances were investigated on site for each case. Illness characteristics, reasons for RZ treatment, doses and frequency of administration of pyrazinamide, monitoring during treatment, and causes of liver injury were determined. Results. Liver injury was attributable to RZ use for all 50 patients reported, 12 of whom died. For 47 patients, RZ was the likeliest cause of liver injury. The median patient age was 44 years (range, 17–73 years). Thirty-two patients (64%) were male. Seven (16%) of 43 patients tested had hepatitis C virus antibodies, 1 (2%) of 45 had chronic hepatitis B, 3 (14%) of 22 had positive results of HIV serologic tests, 34 (71%) of 48 had alcohol use noted, and 33 (66%) of 50 were taking additional hepatotoxic medications. Six patients, 2 of whom died, had no predictors for liver disease. Patients who died were older (median age, 52 vs. 42 years; [FORMULA]) and took a greater number of other medications (median number of medications, 4 vs. 2; [FORMULA]) than did those who recovered, but these 2 factors were correlated ([FORMULA]). Thirty-one patients (62%) were monitored according to guidelines, 9 of whom died. Conclusions. RZ was the likeliest cause of most of these liver injuries, some of which were fatal in spite of monitoring. Fatality was predicted by age or use of other medications, but none of the cofactors showed promise as a reliable clinical predictor of severe liver injury.
Volume 42, number 3: Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampbin and Pyrazinamide for Latent Tuberculosis Infection related news:
- New, more accurate TB test — U.S. News & World Report
- Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation — News-Medical News Feed
- Pumping Chemotherapy Drugs Into Abdomen Extends Lives Of Ovarian Cancer Patients, Despite Severe Side Effects, Study Says — Medical News Today RSS/XML Feed
- New pathways linking liver disease to changes in the central nervous system — News-Medical News Feed
- Volume 42, number 3: Azithromycin-Resistant Syphilis Infection: San Francisco, California, 2000-2004 — Clin Infect Dis Latest Issue
- CDC Updates Guidelines for Immunization Against Hepatitis B Virus Infection — Medscape Med Students Headlines
- Antidepressants work almost immediately — HEALTH
- Volume 42, number 3: Diagnostic Evaluation of Newly Arrived Asymptomatic Refugees with Eosinophilia — Clin Infect Dis Latest Issue
- U.S. faces severe worker shortage in future — USATODAY.com Money - Top Stories
- Cyclosporine inhibits hepatitis C virus in vitro — EurekAlert! - Medicine and Health
Latest news from Clin Infect Dis Latest Issue:
- Volume 43, number S4: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
- Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
- Volume 43, number S4: The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
- Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
- Volume 43, number S4: Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
- Volume 43, number S4: Buprenorphine Use: The International Experience
- Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
- Volume 43, number S4: Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care